e coli superbug is spreading

not-so-shockingly, the US government reported the first case of a patient in the US with colistin-resistant e. coli, in a 49 yo Pennsylvania woman with a urinary tract infection. they found a plasmid-mediated piece of DNA which passed along the mcr-1 gene, conferring colistin resistance (see http://www.reuters.com/article/us-health-superbug-idUSKCN0YH2KT . for the case study, see antibiotic resistance colistin PA antimicagents2016 in dropbox, or doi:10.1128/AAC.01103-16). this is precisely the issue reported last year in China [see http://blogs.bmj.com/ebm/2015/12/10/primary-care-corner-with-geoffrey-modest-md-troubling-microbiome-changes . this blog looked at the initial report from China, noting that China is the world's largest producer of poultry and pig products and one of the largest veterinary users or colistin (aka polymixin E), finding this resistant bug in 16 samples from various sites: sputum, urine, ascitic fluid, bile...]. since the Chinese finding, the  Walter Reed National Military Medical Center has been testing all extended-spectrum b-lactamase-producing e.coli for colistin-resistance.

this current finding and the blog (which goes into detail on the China case) basically make the following points:
--antibiotic resistance is a huge and growing problem: >2 million illnesses blamed on antibiotic resistance in the US with 23,000 annual deaths
--potential for spread of this e coli, resistant to the last-line big gun colistin, is real, and highlighted by this case in the US 6 months after the report in China. the concern is that the ability for e. coli to elaborate plasmid-mediated resistance makes it more spreadable than through the prior identified mechanism of chromosomal changes
--part of the issue is us guys: more than 1/2 of patients admitted to the hospital get an antibiotic, but 30-50% of the time it is considered unnecessary. blogs below look at the overuse of antibiotics in the outpatient setting as well.
--the biggest part of the problem is use/remarkable overuse of antibiotics in agriculture (as in the colistin case), leading to lots of resistant bugs (see blogs below). 
--and there is real concern, as per the cdc, that we may be entering a post-effective antibiotic era
--confounding the issue, is the lack of aggressive antibiotic development by drug companies: even expensive antibiotics (the $100-200/pill ones) are typically given for short, and therefore less-profitable, courses of treatment. the $$ is in longterm, preferably lifelong need for meds.  some of the big drug companies who mostly foreswore against antibiotic drug development have "signed a declaration calling for new incentives from governments to support investment in development of medicines to fight drug-resistant superbugs". perhaps the hepatitis c drug model will develop: hugely overpriced drugs, which even for only a few months can develop huge profits...???

see http://blogs.bmj.com/ebm/category/antimicrobial-resistance/ for a litany of articles/critiques on antibiotic overprescribing, resistance, and efforts to combat resistance, including a US White House report from last year

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure -- i believe these trials (not cited specifically by the FDA) were the ones in the blog
Read more

cystatin c: better predictor of bad outcomes than creatinine

Image
  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr  <15 -- mean urinary albumin-to-creat ratio: 12 mg/g -- comorbidities: hypertension 59%, diabetes 8%, coronary heart di
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardi
Read more